


SUPPLEMENTARY DATA

Supplementary Table S1. qPCR primer list

Symbol	Forward (5'->3')	Reverse (5'->3')	GenBank Accession
sXBP1a	CTGAGTCCGAATCAGGTG CAG	GTCCATGGGAAGATGTTC TGG	NM_001271730
CHOP	CCACCACACCTGAAAGCA GAA	AGGTGAAAGGCAGGGAC TCA	NM_007837
BIP	TTCAGCCAATTATCAGCAA ACTCT	TTTTCTGATGTATCCTCTT CACCAGT	NM_001163434
ATF4	GGGTTCTGTCTTCCACTCC A	AAGCAGCAGAGTCAGGCT TTC	NM_009716
IL-1 β	GCAACTGTTCTGAAGTCA ACT	ATCTTTTGGGGTCCGTCA ACT	NM_008361
IL-6	TAGTCCTTCCTACCCCAAT TTCC	TTGGTCCTTAGCCACTCCT TC	NM_031168
TNF α	CCCTCACACTCAGATCATC TTCT	GCTACGACGTGGGCTACA G	NM_013693
AGRP	CGGCCACGAACCTCTGTA G	CTCATCCCCTGCCTTTGC	NM_007427
NPY	TCCGCTCTGCGACTACA T	GGGACAGGCAGACTGGTT TC	NM_023456
POMC	GAGGCCACTGAACATCTTT GTC	GCAGAGGCAAACAAGAT TGG	NM_001278581
LepRb	GGAGCCATTACCTAAGAA CCC	TGACATTCACATCCCCGA AG	NM_001122899
SOCS3	AGAGCGGATTCTACTGGA GC	TGGATGCGTAGGTTCTTG GTC	NM_007707
PTP1B	ACGGCGTACCTGGTCATCT A	CTATGGTAGCTCCCCTTA GCC	NM_023587
UCP1	AAGCTGTGCGATGTCCATG T	AAGCCACAAACCCTTTGA AAA	NM_009463
PGC1a	AGACAAATGTGCTTCCAA AAAGAA	GAAGAGATAAAGTTGTTG GTTTGG	NM_008904
CIDEA	GGTTCAAGGCCGTGTTAA GG	CGTCATCTGTGCAGCATA GG	NM_007702
PRDM16	CCACCAGCGAGGACTTCA C	GGAGGACTCTCGTAGCTC GAA	NM_027504
Pnpla2	CAACGCCACTCACATCTAC GG	GGACACCTCAATAATGTT GGCA	NM_001163689
β 3AR	TCCTTCTACCTTCCCCTCCT T	CGGCTTAGCCACAACGAA CAC	NM_013462
Ppib	TGGAGAGCACCAAGACAG ACA	TGCCGGAGTCGACAATGA T	NM_011149


SUPPLEMENTARY DATA

Supplementary Figure S1. Changes of the levels of gene expressions in the liver by celastrol treatment. (A-C) Expression levels of genes involved in ER stress. (D-F) Expression levels of inflammatory cytokine genes. (N=4-6/group). Data are presented as mean \pm SEM.




SUPPLEMENTARY DATA

Supplementary Figure S2. Celastrol treatment does not improve blunted leptin-induced pSTAT3 in mediobasal hypothalamus of DIO mice. (A) Five days of systemic Celastrol (IP, 0.5 mg/Kg) drastically reduce body weight in DIO mice (n=3/group). (B, C) Representative images showing baseline pSTAT3 in the mediobasal hypothalamus of DIO mice received either vehicle (B) or Celastrol treatment (C). (D-F) Representative images showing leptin-induced pSTAT3 in mediobasal hypothalamus of vehicle-treated chow-fed control (D and DIO (E) and Celastrol-treated DIO (F) mice. Note that no perceivable improvement of baseline or blunted leptin-induced pSTAT3 in mediobasal hypothalamus of DIO by Celastrol treatment. (N=3/group). ***p<0.0001 vs DIO by two-way ANOVA compared to vehicle group. Data are presented as mean ± SEM.



SUPPLEMENTARY DATA

Supplementary Figure S3. Changes of the levels of gene expressions in the hypothalamus by celastrol. (A-G) Expression levels of genes encoding different G alpha subunits. (E-G) Expression levels of genes encoding different family members of RGS (N=4-6/group). * $p < 0.05$, ** $p < 0.01$ by Student's t-test (compared to Vehicle group). Data are presented as mean \pm SEM.



SUPPLEMENTARY DATA

Supplementary Figure S4. Celastrol treatment reduce ambulatory activity as measured by beam break system. (N=8/group). **p<0.01, ***<0.001 by two-way ANOVA compared to Vehicle group. Data are presented as mean ± SEM.

